|View printer-friendly version|
Seattle Genetics Announces Date of Second Quarter Results and Conference Call
July 11, 2001 at 12:00 AM EDT
BOTHELL – July 11, 2001 --- Seattle Genetics (Nasdaq: SGEN) will release second quarter 2001 results on Tuesday, July 24, 2001, after the close of U.S. financial markets. This announcement will be available on the Seattle Genetics website at www.seattlegenetics.com.
Additionally, Seattle Genetics executives will host a conference call to discuss the results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern) on July 24th. A webcast of the live call can be accessed from the “News and Investor Information/audio presentations” section of the Company’s website. The webcast will also be archived and available starting shortly after the conclusion of the call until 6:00 p.m. Pacific Time on Thursday, July 26, 2001 from the Company’s website.
About Seattle Genetics
Seattle Genetics discovers and develops monoclonal antibody, or mAb, -based therapeutics to treat cancer and related diseases. The Company utilizes its mAb-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. Seattle Genetics has four mAb-based technologies: engineered mAbs, mAb-drug conjugates, single-chain immunotoxins and antibody-directed enzyme prodrug therapy. Using these technologies and its expertise in cancer, Seattle Genetics has built a diverse portfolio of drug candidates targeted to many types of human cancers, including two currently being tested in clinical trials. The Company also out-licenses its mAb-based technologies to strategic partners developing targeted therapies. More information about Seattle Genetics can be found at www.seattlegenetics.com.